Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 26 Nov 2018 |
| Zealand Pharma - Interim report for the first nine months of 2018 | 15 Nov 2018 |
| Zealand announces amendments to its Articles of Association following the granting of warrants | 26 Oct 2018 |
| Zealand grants new warrants under employee warrant program | 15 Oct 2018 |
| Total number of shares and voting rights in Zealand Pharma at September 28, 2018 | 28 Sept 2018 |